Article
Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 1 Dec 2016
De Ruysscher Dirk, Defraene Gilles, Ramaekers Bram L T, Lambin Philippe, Briers Erik, Stobart Hilary, Ward Tim, Bentzen Søren M, Van Staa Tjeerd, Azria David, Rosenstein Barry, Kerns Sarah, West Catharine
Abstract excerpt
The optimal design and patient selection for interventional trials in radiogenomics seem trivial at first sight. However, radiogenomics do not give binary information like in e.g. targetable mutation biomarkers. Here, the risk to develop severe side effects is continuous, with increasing incidences of side effects with higher doses and/or volumes. In addition, a multi-SNP assay will produce a predicted...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.